shinjini ganguli

Bengaluru: The U.S. health regulator’s staff on Wednesday flagged concerns that data on Merck’s chronic cough drug might not be enough to prove the treatment’s meaningful benefit, documents released ahead of a meeting of independent experts showed. Shares of the drugmaker were down nearly 1 per cent at $101.2 in afternoon trade. The concerns were … Read more